{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:03:09Z","timestamp":1789689789687,"version":"4.0.1"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Krka d.d., Novo Mesto, Slovenia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background The use of oral anticoagulants (OACs), especially direct oral anticoagulants (DOACs), for thromboprophylaxis in atrial fibrillation (AF) has increased over the last decade, and an increasing number of generic DOAC medications (particularly regarding rivaroxaban and apixaban) have been marketed recently. The aim of the present study was to prospectively observe clinical event rates and patient satisfaction with a generic rivaroxaban for thromboprophylaxis in patients with AF.<\/jats:p>\n                  <jats:p>Methods Adult patients with AF in whom long-term OAC was indicated for thromboprophylaxis were included in this international, prospective, non-interventional, observational study with 1-year follow-up, conducted in the Republic of Serbia and Bosnia and Herzegovina. Data were collected at baseline and 3-, 6-, and 12-month follow-up visits. The primary endpoints were stroke\/systemic embolism (SE), major bleeding, and all-cause mortality. Secondary endpoints included adverse events and patient satisfaction with generic rivaroxaban therapy.<\/jats:p>\n                  <jats:p>Results Of 1092 patients (mean age 67.9 \u00b1 9.8, 42.9% female), 72 (6.6%) discontinued the treatment due to different reasons. The mean value of the CHA2DS2\u2013VASc score (Congestive heart failure, Hypertension, Age &gt;75 years, Diabetes mellitus, Stroke, Vascular disease, Age 65\u201374 years, Sex category) and HAS\u2013BLED (Hypertension [uncontrolled], Abnormal renal and\/or liver function, Stroke history, Bleeding history, Labile International Normalised Ratio, Elderly [&gt;65 years], Drugs [non-steroidal anti-inflammatory drugs, aspirin]\/Alcohol use [&gt;8 drinks per week]) score was 3.15 \u00b1 1.55 and 1.18 \u00b1 0.92, respectively. Overall, seven patients (0.64%) experienced a symptomatic thromboembolic event (two strokes, three transient ischaemic attack, and two SE), and major bleeding occurred in two patients (0.18%). At the 3-, 6- and 12-month follow-up visits, 1068 (97.8%), 1031 (94.4%) and 1014 participants (92.9%), respectively, were still taking generic rivaroxaban. At 3 and 12 months, 1024\/1071 patients (95.6%) and 1005\/1020 (98.5%), respectively, were very satisfied or satisfied with generic rivaroxaban.<\/jats:p>\n                  <jats:p>Conclusions The observed clinical event rates during the use of generic rivaroxaban in AF patients were low, with very good 1-year persistence to treatment and persistently high level of patient satisfaction with generic rivaroxaban, including those previously taking another OAC. More studies with larger sample size are needed to allow additional analyses of factors associated with specific outcomes, including non-persistence to treatment with generic rivaroxaban.<\/jats:p>","DOI":"10.1055\/a-2949-8821","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:05:45Z","timestamp":1788476745000},"source":"Crossref","is-referenced-by-count":0,"special_numbering":"S","title":["Clinical Event Rates and Patient Satisfaction with Generic Rivaroxaban in Atrial Fibrillation: The Prospective Guardian Study"],"prefix":"10.1055","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-6902","authenticated-orcid":false,"given":"Tatjana","family":"Potpara","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade, Serbia","place":["Belgrade"]},{"name":"Cardiology Clinic, University Clinical Centre of Serbia, Serbia","place":["Belgrade"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belma","family":"Pojski\u0107","sequence":"additional","affiliation":[{"name":"Zenica Cantonal Hospital, Faculty of Medicine, University of Zenica, Federation of Bosnia and Herzegovina, Bosnia and Herzegovina","place":["Zenica"],"department":["Department of General Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Ota\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade, Serbia","place":["Belgrade"]},{"name":"Cardiology Clinic, Institute for Cardiovascular Diseases \u201cDedinje\u201d, Serbia","place":["Belgrade"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neboj\u0161a","family":"Mujovi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade, Serbia","place":["Belgrade"]},{"name":"Cardiology Clinic, University Clinical Centre of Serbia, Serbia","place":["Belgrade"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milovan","family":"Petrovi\u0107","sequence":"additional","affiliation":[{"name":"Cardiology Clinic, Institute of Cardiovascular Diseases of Vojvodina, Serbia","place":["Novi Sad"]},{"name":"Faculty of Medicine, University of Novi Sad, Vojvodina, Serbia","place":["Novi Sad"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Zdravkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medical Sciences, University of Kragujevac, Serbia","place":["Kragujevac"]},{"name":"Clinic of Cardiology, University Clinical Centre Kragujevac, Serbia","place":["Kragujevac"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugdim","family":"Bajri\u0107","sequence":"additional","affiliation":[{"name":"Clinic for Invasive Cardiology, University Clinical Centre of Tuzla, Bosnia and Herzegovina","place":["Tuzla"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Un\u010danin","sequence":"additional","affiliation":[{"name":"Cardiology Clinic, University Clinical Center of Republic of Srpska, Bosnia and Herzegovina","place":["Banja Luka"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Dragojevi\u0107-Stoji\u0107","sequence":"additional","affiliation":[{"name":"Public Hospital Dr. Mladen Stojanovi\u0107, Bosnia and Herzegovina","place":["Prijedor"],"department":["Department of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Kunarac","sequence":"additional","affiliation":[{"name":"University Hospital Fo\u010da, Bosnia and Herzegovina","place":["Fo\u010da"],"department":["Department of Cardiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bojan","family":"Pejovi\u0107","sequence":"additional","affiliation":[{"name":"Public Hospital Srbija, East Sarajevo, Bosnia and Herzegovina","place":["Sarajevo"],"department":["Department of Internal Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Bedak","sequence":"additional","affiliation":[{"name":"General Hospital Te\u0161anj, Bosnia and Herzegovina","place":["Te\u0161anj"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samed","family":"Djedovi\u0107","sequence":"additional","affiliation":[{"name":"MIB Medical Institute Bayer, Bosnia and Herzegovina","place":["Tuzla"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Marinkovi\u0107","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of Belgrade, Serbia","place":["Belgrade"]},{"name":"Cardiology Clinic, University Clinical Centre of Serbia, Serbia","place":["Belgrade"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"G Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"36","key":"ref2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"I C Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"149","author":"J A Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.cpcardiol.2023.102181","article-title":"Atrial fibrillation and stroke: state-of-the-art and future directions","volume":"49","author":"S Elsheikh","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"100797","DOI":"10.1016\/j.lanepe.2023.100797","article-title":"Atrial fibrillation: stroke prevention","volume":"37","author":"T F Chao","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/ehjqcco\/qcae022","article-title":"Contemporary trends in incident ischaemic stroke, intracranial haemorrhage, and mortality in individuals with atrial fibrillation","volume":"11","author":"J J Noubiap","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/pds.5650","article-title":"Heterogeneity after harmonisation: a retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries","volume":"32","author":"J J Komen","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"100784","DOI":"10.1016\/j.lanepe.2023.100784","article-title":"Atrial fibrillation: comorbidities, lifestyle, and patient factors","volume":"37","author":"E Shantsila","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.tcm.2023.04.001","article-title":"Benefits of early rhythm control of atrial fibrillation","volume":"34","author":"L Eckardt","year":"2024","journal-title":"Trends Cardiovasc Med"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"P Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1055\/a-2469-4896","article-title":"An international consensus practical guide on left atrial appendage closure for the non-implanting physician: executive summary","volume":"125","author":"T Potpara","year":"2025","journal-title":"Thromb Haemost"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/europace\/euz032","article-title":"Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF general long-term registry","volume":"21","author":"G Boriani","year":"2019","journal-title":"Europace"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/ehjqcco\/qcaa050","article-title":"Cohort profile: the ESC EURObservational research programme atrial fibrillation III (AF III) registry","volume":"7","author":"T S Potpara","year":"2021","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European registry in atrial fibrillation (PREFER in AF)","volume":"16","author":"P Kirchhof","year":"2014","journal-title":"Europace"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"euaf250","DOI":"10.1093\/europace\/euaf250","article-title":"Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians","volume":"27","author":"T Potpara","year":"2025","journal-title":"Europace"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2024.01.017","article-title":"A comparative in vitro study of the anticoagulant effect of branded versus generic rivaroxaban","volume":"235","author":"K Mangion","year":"2024","journal-title":"Thromb Res"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist Oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"J Steffel","year":"2021","journal-title":"Europace"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"S Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","article-title":"Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers","volume":"8","author":"M J Atkinson","year":"2005","journal-title":"Value Health"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12916-022-02526-7","article-title":"Clinical complexity and impact of the ABC (atrial fibrillation better care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational research programme in AF general long-term registry","volume":"20","author":"G F Romiti","year":"2022","journal-title":"BMC Med"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/jce.13428","article-title":"Overweight and obesity in patients with atrial fibrillation: sex differences in 1-year outcomes in the EORP-AF general pilot registry","volume":"29","author":"G Boriani","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"20432","DOI":"10.1038\/srep20432","article-title":"Stroke prevention in atrial fibrillation and \u2018real world\u2019 adherence to guidelines in the Balkan region: the BALKAN-AF survey","volume":"6","author":"T S Potpara","year":"2016","journal-title":"Sci Rep"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/europace\/euu201","article-title":"Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry","volume":"17","author":"G Y Lip","year":"2015","journal-title":"Europace"},{"issue":"14","key":"ref25","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"A J Camm","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"ref27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"C B Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"M R Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"ref29","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"R P Giugliano","year":"2013","journal-title":"N Engl J Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"euad226","DOI":"10.1093\/europace\/euad226","article-title":"Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal","volume":"25","author":"G YH Lip","year":"2023","journal-title":"Europace"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"6707985","DOI":"10.1155\/2022\/6707985","article-title":"Time trends and treatment pathways in prescribing individual Oral anticoagulants in patients with Nonvalvular atrial fibrillation: an observational study of more than three million patients from Europe and the United States","volume":"2022","author":"P Vora","year":"2022","journal-title":"Int J Clin Pract"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/europace\/euu319","article-title":"Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry","volume":"17","author":"J Beyer-Westendorf","year":"2015","journal-title":"Europace"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"e034778","DOI":"10.1136\/bmjopen-2019-034778","article-title":"Adherence to oral anticoagulants among patients with atrial fibrillation: a systematic review and meta-analysis of observational studies","volume":"10","author":"S Salmasi","year":"2020","journal-title":"BMJ Open"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"e005969","DOI":"10.1161\/CIRCOUTCOMES.119.005969","article-title":"Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"13","author":"A F Ozaki","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"04","key":"ref35","doi-asserted-by":"crossref","first-page":"e239638","DOI":"10.1001\/jamanetworkopen.2023.9638","article-title":"Patients and their physician\u2019s perspectives about oral anticoagulation in patients with atrial fibrillation not receiving an anticoagulant","volume":"6","author":"C P Cannon","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"E D Borre","year":"2018","journal-title":"Thromb Haemost"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"R Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"D A Mei","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/jth.15415","article-title":"GARFIELD-AF investigators. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF registry","volume":"19","author":"F Cools","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref40","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/bcp.13985","article-title":"A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants","volume":"85","author":"S K Afzal","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"03","key":"ref41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0040-1716752","article-title":"Satisfaction of patients with nonvitamin K anticoagulants compared to vitamin k antagonists: a systematic review and meta-analysis","volume":"121","author":"V Katerenchuk","year":"2021","journal-title":"Thromb Haemost"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.cjco.2021.06.015","article-title":"Satisfaction with oral anticoagulants among patients with atrial fibrillation: a prospective observational study","volume":"3","author":"S Salmasi","year":"2021","journal-title":"CJC Open"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1536\/ihj.17-649","article-title":"Patient satisfaction with direct oral anticoagulants and warfarin","volume":"59","author":"Y Okumura","year":"2018","journal-title":"Int Heart J"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2949-8821.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:06:01Z","timestamp":1789686361000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2949-8821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":43,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2026,1,9]]},"published-print":{"date-parts":[[2026]]}},"alternative-id":["a29498821"],"URL":"https:\/\/doi.org\/10.1055\/a-2949-8821","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,3]]},"published":{"date-parts":[[2026,9,3]]}}}